

International Conference on

CANCER EPIGENETICS AND BIOMARKERS

October 26-28, 2017 Osaka, Japan

Cancer treatment using newly synthesized natural compound

Young-Seok Lee

Kyung Hee University, South Korea

Our lab synthesizing new compounds, compound A, based on natural extracts. Compound A was modified by some residues of natural extracts. Compound A has lower side effects than well-known anticancer agents and has a higher cancer therapeutic effect than from backbone natural extracts used in the production of Compound A. Our experimental results that cell viability was decreased in dose-dependent manner via the MTS assay. Compound A repressed cell viability of HepG2 cell line after 24 hours treatment with dose ranged from 25 μ M to 100 μ M. We also confirm the cell death marker through Western blotting and FACs analysis and investigated that compound A induces apoptosis. In western blot data, Compound A was treated for 24 hours, dose-dependent manner on HepG2 cells and the apoptosis marker protein Cleaved-Caspase 3, Cleaved-PARP was dose-dependently increased. In addition, the pro-apoptotic marker Bax increased and anti-apoptotic marker Bcl2 was decreased. In FACs data, HepG2 cells were exposed to Compound A for 24 hours, which resulted in an accumulation of cells in G2/Mphase. According our data, we expect that we develop promising therapeutic agents that are lower price than the well-known drugs for liver cancer and have lower side effects and higher effectiveness using Compound A.

Biography

Young-Seok Lee has completed his Master's degree at Kyunghee University, Seoul, South Korea. Presently, he is a Doctoral student, studying about liver cancer therapy using newly-synthesized compound and protein proteasomal-degradation.

wetoo123@gmail.com

Notes: